Back

Managing dyslipidemia in the elderly: efficacy and safety of bempedoic acid in very high-risk patients

4 April 2025 (09:00 - 18:00)
Organised by: Logo
Congress Presentation Part of: Poster session (2) Cardiovascular Disease in the Elderly EAPC Premium Access ESC Preventive Cardiology 2025 European Association of Preventive Cardiology (EAPC)

About the speaker

Photo
Doctor Emanuele Di Marco

Policlinico Tor Vergata, Rome (Italy)

87 More presentations in this session

Presentation thumbnail
Comparative efficacy and safety of antithrombotic regimens following left atrial appendage occlusion therapy in atrial fibrillation patients: a comprehensive Bayesian network meta-analysis
Doctor V. Lanari (Milan, IT)
Abstract Slides
Presentation thumbnail
Paroxysmal atrial fibrillation prediction score based on 24-hours electrocardiogram-monitoring data
Doctor G. Galati (Milan, IT)
Abstract Slides
Presentation thumbnail
Is excessive epicardial fat volume in asymptomatic young adult subjects with normal calcium score the trigger for abnormal ECGs and arrhythmia?
Doctor A. Sabatini (Florence, IT)
Abstract Slides
Presentation thumbnail
Prevention of readmission in the acute setting for heart failure patients: an adapted protocol of levosimendan infusion in inpatient high-intensity cardiac rehabilitation
Doctor I. Cusmano (Milan, IT)
Abstract Slides
Presentation thumbnail
Enhanced external counterpulsation (EECP) as a strategy for left ventricular and microcirculatory improvement: independent of cardiac intervention
Doctor O. Handayani (Jakarta, ID)
Abstract Slides

Access the full session

Session thumbnail
Poster session (2)

The Event

Event poster

ESC Preventive Cardiology 2025

4 April 2025 09:00 CET
You may be interested in
thumbnail
Congress Presentation
New treatments for dyslipidemia in older patients? Real-life analysis of the use of bempedoic acid in the elderly population.
thumbnail
Congress Presentation
Impact of bempedoic acid alone and combined with ezetimibe on ldl-cholesterol reduction: graphical evidence and retrospective analysis of a real-world clinical cohort
thumbnail
Congress Presentation
Time course of LDL-C lowering after initiation of PCSK9 inhibition or bempedoic acid in atherosclerotic cardiovascular disease

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources